Physician profile
Amanda M Applegate
NPI 1831180967
$6,197.17
in general payments reported to CMS, 2019-2025
36 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $628 · 2021: $624 · 2022: $739 · 2023: $1,294 · 2024: $1,218 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,593.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $982.42 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $886.08 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Novo Nordisk INC | $822.72 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $606.65 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $407.24 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Otsuka America Pharmaceutical, INC. | $337.81 | 2022-2025 | Rexulti |
| Pfizer INC. | $224.31 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $192.43 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.44 | 2020-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $172.57 | 2019-2024 | M-M-R II, Gardasil, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $172.03 | 2019-2022 | |
| Abbott Laboratories | $134.85 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $134.41 | 2022-2025 | |
| Allergan, INC. | $125.05 | 2020 | |
| Janssen Pharmaceuticals, INC | $109.05 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $107.25 | 2023-2025 | Gemtesa |
| Lundbeck LLC | $91.77 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $66.25 | 2023-2025 | Auvelity |
| Exact Sciences Corporation | $64.57 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $41.12 | 2022 | |
| Eisai INC. | $31.19 | 2020 | |
| Nabriva Therapeutics, Plc | $28.94 | 2022 | |
| Lemaitre Vascular, INC. | $28.19 | 2024 | Artegraft Vascular Graft |
| Vanda Pharmaceuticals INC. | $27.58 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $23.55 | 2020-2022 | |
| Glaxosmithkline, LLC. | $23.23 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.75 | 2019-2020 | |
| Dexcom, INC. | $20.70 | 2025 | Dexcom G6 Transmitter |
| Evoke Pharma, INC. | $20.57 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.71 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $17.72 | 2021 | |
| Abiomed | $14.47 | 2024 | Impella |
| Amarin Pharma, INC. | $13.09 | 2019 | |
| Genentech USA, INC. | $11.34 | 2021 | |
| Shire North American Group INC | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Applegate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.